These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 29318594)

  • 21. Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
    Cai ZW; Liu J; Li HY; Sheppard DN
    Acta Pharmacol Sin; 2011 Jun; 32(6):693-701. PubMed ID: 21642944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    Chung WJ; Goeckeler-Fried JL; Havasi V; Chiang A; Rowe SM; Plyler ZE; Hong JS; Mazur M; Piazza GA; Keeton AB; White EL; Rasmussen L; Weissman AM; Denny RA; Brodsky JL; Sorscher EJ
    PLoS One; 2016; 11(10):e0163615. PubMed ID: 27732613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation.
    Cholon DM; Esther CR; Gentzsch M
    Expert Rev Precis Med Drug Dev; 2016; 1(3):235-243. PubMed ID: 27482545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
    Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
    Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.
    Yu YC; Sohma Y; Hwang TC
    J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622.
    Norez C; Bilan F; Kitzis A; Mettey Y; Becq F
    J Pharmacol Exp Ther; 2008 Apr; 325(1):89-99. PubMed ID: 18230692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.
    Van Goor F; Hadida S; Grootenhuis PD; Burton B; Cao D; Neuberger T; Turnbull A; Singh A; Joubran J; Hazlewood A; Zhou J; McCartney J; Arumugam V; Decker C; Yang J; Young C; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu P
    Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18825-30. PubMed ID: 19846789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
    Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
    Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Full Rescue of F508del-CFTR Processing and Function by CFTR Modulators Can Be Achieved by Removal of Two Regulatory Regions.
    Uliyakina I; Botelho HM; da Paula AC; Afonso S; Lobo MJ; Felício V; Farinha CM; Amaral MD
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
    Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
    Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222.
    Singh AK; Fan Y; Balut C; Alani S; Manelli AM; Swensen AM; Jia Y; Neelands TR; Vortherms TA; Liu B; Searle XB; Wang X; Gao W; Hwang TC; Ren HY; Cyr D; Kym PR; Conrath K; Tse C
    J Pharmacol Exp Ther; 2020 Jan; 372(1):107-118. PubMed ID: 31732698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating.
    Yang H; Shelat AA; Guy RK; Gopinath VS; Ma T; Du K; Lukacs GL; Taddei A; Folli C; Pedemonte N; Galietta LJ; Verkman AS
    J Biol Chem; 2003 Sep; 278(37):35079-85. PubMed ID: 12832418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentiation of cystic fibrosis transmembrane conductance regulator (CFTR) Cl- currents by the chemical solvent tetrahydrofuran.
    Hughes LK; Ju M; Sheppard DN
    Mol Membr Biol; 2008 Sep; 25(6-7):528-38. PubMed ID: 18989824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.
    Van Goor F; Hadida S; Grootenhuis PD; Burton B; Stack JH; Straley KS; Decker CJ; Miller M; McCartney J; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu PA
    Proc Natl Acad Sci U S A; 2011 Nov; 108(46):18843-8. PubMed ID: 21976485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation.
    Pasyk S; Molinski S; Ahmadi S; Ramjeesingh M; Huan LJ; Chin S; Du K; Yeger H; Taylor P; Moran MF; Bear CE
    Proteomics; 2015 Jan; 15(2-3):447-61. PubMed ID: 25330774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A.
    Lopes-Pacheco M; Bacalhau M; Ramalho SS; Silva IAL; Ferreira FC; Carlile GW; Thomas DY; Farinha CM; Hanrahan JW; Amaral MD
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator.
    Schmidt A; Hughes LK; Cai Z; Mendes F; Li H; Sheppard DN; Amaral MD
    Br J Pharmacol; 2008 Mar; 153(6):1311-23. PubMed ID: 18223673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.
    Bongiorno R; Ludovico A; Moran O; Baroni D
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.